Some Proteomics Firms Exploring Next-Generation Sequencing for Biomarker Research

Anticipating that NGS will become a key clinical tool in coming years, several proteomics firms and researchers are investigating it as a platform for protein biomarker detection assays that use nucleotides as capture agents, hoping to take advantage of the technology's precision and multiplexing ability.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.